PCN3 Changes in Transfusion Burden (TB), Hemoglobin (Hb), Serum Ferritin (SF), and Iron Chelation Therapy (ICT) Use in Patients With Lower-Risk Myelodysplastic Syndromes With Ring Sideroblasts Treated With Luspatercept From the MEDALIST Study